Compare SBCF & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | RVPH |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 71.0M |
| IPO Year | N/A | N/A |
| Metric | SBCF | RVPH |
|---|---|---|
| Price | $32.51 | $0.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $31.00 | $3.33 |
| AVG Volume (30 Days) | 593.2K | ★ 4.3M |
| Earning Date | 01-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 23.57 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $556,541,000.00 | N/A |
| Revenue This Year | $33.11 | N/A |
| Revenue Next Year | $30.09 | N/A |
| P/E Ratio | $19.39 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $21.36 | $0.25 |
| 52 Week High | $33.23 | $2.95 |
| Indicator | SBCF | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 58.18 |
| Support Level | $31.97 | $0.60 |
| Resistance Level | $33.17 | $0.77 |
| Average True Range (ATR) | 0.77 | 0.05 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 77.92 | 61.01 |
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.